Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxirane SCHEMBL3757849 | 0.76 | — | — | |
| SCHEMBL11398596 | 0.64 | HTR1A (0.36) | KDM4ETYMS | |
| SCHEMBL15828537 | 0.57 | ALDH1A1 (0.39) | KDM4EALDH1A1TYMSCYP1A2HPGD | |
| SCHEMBL10967544 | 0.56 | CA12 (0.41) | KDM4EALDH1A1TYMSCYP1A2HPGD | |
| SCHEMBL4499653 | 0.55 | HSD17B3 (0.38) | KDM4EALDH1A1TYMSCYP1A2HPGD | |
| SCHEMBL28419063 | 0.55 | PRF1 (0.38) | KDM4EALDH1A1TYMSCYP1A2HPGD | |
| Hydrochloric Acid SCHEMBL28215018 | 0.54 | KMT2A (0.41) | KDM4EALDH1A1TYMSCYP1A2HPGD | |
| Ammonia Solution, Strong SCHEMBL20994638 | 0.54 | KMT2A (0.41) | KDM4EALDH1A1TYMSCYP1A2HPGD | |
| SCHEMBL28989965 | 0.54 | KMT2A (0.41) | KDM4EALDH1A1TYMSCYP1A2HPGD | |
| SCHEMBL14373225 | 0.53 | HSD17B10 (0.59) | KDM4EALDH1A1TYMSCYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347345-B1 | MIXED SOLVATE OF (R)-5-[2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL]-8-HYDROXY-1H-QUINOLIN-2-ONE L-TARTRATE | INKE SA (ES) | 2019-07-31 | — | — | EP | disclosed |
| US-9040559-B2 | BETA2-adrenoceptor agonists | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8796307-B2 | Beta2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | NOVARTIS AG (CH) | 2014-03-06 | — | — | US | disclosed |
| US-8658673-B2 | BETA2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2014-02-25 | — | — | US | disclosed |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8436017-B2 | Beta-2-adrenoreceptor agonists | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2332915-B1 | Beta2-adrenoceptor agonists | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | CUENOUD BERNARD (GB) | 2012-11-29 | — | — | US | disclosed |
| US-20050009795-A1 | Mixtures or organic compounds for the treatment of airway diseases | CUENOUD BERNARD (CH) | 2005-01-13 | — | — | US | disclosed |
| US-6800643-B2 | CORTICOSTEROID AND AN INDANYL-QUINOLINONE COMPOUND | NOVARTIS AG (CH) | 2004-10-05 | — | — | US | disclosed |
| US-20040038951-A1 | Organic compounds | NOVARTIS AG (CH) | 2004-02-26 | — | — | US | disclosed |
| EP-1341542-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002045703-A2 | MIXTURES OR ORGANIC COMPOUNDS FOR THE TREATMENTOF AIRWAY DISEASES | NOVARTIS AG (CH) | 2002-06-13 | — | — | WO | disclosed |
| EP-1183240-A1 | BETA2-ADRENOCEPTOR AGONISTS | Novartis AG (CH) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000075114-A1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2000-12-14 | — | — | WO | disclosed |
| US-5750701-A | Heterocyclic ethanolamine derivatives with β-adrenoreceptor agonistic activity | SMITHKLINE BEECHAM PLC (GB) | 1998-05-12 | — | — | US | disclosed |
| EP-0750617-A1 | NOVEL HETEROCYCLIC ETHANOLAMINE DERIVATIVES WITH BETA-ADRENORECEPTOR AGONISTIC ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025104-A1 | NOVEL HETEROCYCLIC ETHANOLAMINE DERIVATIVES WITH BETA-ADRENORECEPTOR AGONISTIC ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 1995-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066478-A1 | Beta2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | KDM4E 4633/4885ALDH1A1 2969/4885TYMS 4441/4885 |
| US-20140343091-A1 | BETA2-ADRENOCEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | KDM4E 4041/4885ALDH1A1 3219/4885TYMS 4222/4885 |
| US-20040038951-A1 | Organic compounds | CYP11B2, NR3C2, CYP11B1 | KDM4E 4495/4885ALDH1A1 827/4885TYMS 1050/4885 |
| US-20130231367-A1 | BETA2-ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRB3 | KDM4E 4706/4885ALDH1A1 3071/4885TYMS 4446/4885 |
| US-20050009795-A1 | Mixtures or organic compounds for the treatment of airway diseases | NR3C2, CYP11B2, NR3C1 | KDM4E 4810/4885ALDH1A1 1293/4885TYMS 1050/4885 |
| US-20120302531-A1 | beta-2-Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | KDM4E 4461/4885ALDH1A1 2766/4885TYMS 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.